Ibrance: FDA has expanded approved use of metastatic breast cancer treatment to include male patients
The FDA ( U.S. Food and Drug Administration ) has extended the indication of Ibrance ( Palbociclib ) capsules in combination with specific endocrine therapies for hormone receptor-positive ( HR+ ), human epidermal growth factor receptor 2-negative ( HER2- ) advanced or metastatic breast cancer in male patients.
Breast cancer is rare in males with only 2,670 cases of male breast cancer estimated in 2019, less than 1% of all cases of breast cancer.
The majority of breast tumors in male patients express hormone receptors.
Men are more likely to be diagnosed at an older age, with a more advanced stage of disease. Metastatic breast cancer is breast cancer that has spread beyond the breast to other organs in the body ( most often the bones, lungs, liver or brain ).
When breast cancer is hormone-receptor positive, patients may be treated with hormone therapy ( endocrine therapy ) or chemotherapy.
Endocrine therapy slows or stops the growth of hormone-sensitive tumors by blocking the body’s ability to produce hormones or by interfering with effects of hormones on breast cancer cells. There are several FDA-approved endocrine based therapies available for HR-positive metastatic breast cancer patients. Certain treatments are gender-neutral in their indication, but some therapies have been approved only for women, although they are often prescribed for male patients. According to the current clinical practice standards, male patients with breast cancer are treated similarly to women with breast cancer.
Ibrance was initially approved in 2015. It is a kinase inhibitor, approved in combination with an aromatase inhibitor as the first hormonal-based therapy in women who have gone through menopause and in men, or with Fulvestrant in patients whose disease progressed following hormonal therapy.
Pfizer provided the results of an analysis of real-world data ( RWD ) from electronic health records ( EHRs ) as additional supportive data to characterize the use of Palbociclib in combination with endocrine therapy ( aromatase inhibitor or Fulvestrant ) in male patients with breast cancer based on observed tumor responses in this rare subset of patients with breast cancer.
The most common side effects of patients taking Ibrance are infections, leukopenia ( low levels of white blood cells ), fatigue, nausea, stomatitis ( inflammation of the mouth and lips ), anemia ( low levels of red blood cells ), hair loss, diarrhea and thrombocytopenia ( low levels of thrombocytes, also known as platelets, in the blood ).
Other common side effects reported are rash, vomiting, decreased appetite, asthenia ( abnormal physical weakness or lack of energy ) and fever.
Health care providers are advised to monitor a patient’s blood count for neutropenia ( low levels of white blood cells called neutrophils ).
Patients should have their blood count checked prior to starting Ibrance and at the beginning of each cycle, as well as on day 15 of the first two cycles and as clinically indicated.
Because of the potential for genotoxicity, health care providers are advised to tell male patients with female partners of reproductive potential to use effective contraception during treatment with Ibrance and for three months after the last dose.
Women who are pregnant or breastfeeding should not take Ibrance because it may cause harm to a developing fetus or newborn baby. ( Xagena )
Source: FDA, 2019
PAOLA-1 trial: Olaparib has met primary endpoint as first-line maintenance treatment with Bevacizumab for advanced ovarian cancer
Positive results from the phase 3 PAOLA-1 trial in women with advanced ovarian cancer. were announced. The trial, in the...
Trastuzumab deruxtecan has demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer
The results for the pivotal phase II DESTINY-Breast01 trial of Trastuzumab deruxtecan ( DS-8201 ). The HER2-targeting antibody drug conjugate...
The US Food and Drug Administration ( FDA ) has approved Bavencio ( Avelumab ) in combination with Inlyta (...
Lynparza for 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer, approved in the EU
The European Commission ( EC ) has approved Lynparza ( Olaparib ) as a 1st-line maintenance treatment for women with...
Talzenna, a PARP inhibitor, approved in European Union for germline BRCA-mutated locally advanced or metastatic breast cancer
The European Commission has approved Talzenna ( Talazoparib ), an oral poly (ADP-ribose) polymerase ( PARP ) inhibitor, as monotherapy...
For patients with prostate cancer, treating the disease with androgen deprivation therapy ( ADT ) is linked to a...
Nivolumab plus Ipilimumab - Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers
Neoadjuvant, or pre-surgical, treatment with Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) resulted in an overall major pathologic...
European Commission has approved Cabometyx for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma
The European Commission ( EC ) has approved Cabometyx ( Cabozantinib ) 20, 40, 60 mg for the first-line treatment...
ALK+ advanced non-small cell lung cancer: safety and clinical activity results from a study of Alectinib plus Atezolizumab
Alectinib ( Alecensa ) has proven systemic and CNS efficacy in patients with ALK+ aNSCLC ( advanced non-small cell lung...